Author

J. Rogado

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Venous and arterial thromboembolic events associated with osimertinib in patients with lung cancer: a study by the thrombosis and cancer group of the spanish society of medical oncology (SEOM).

PURPOSE To determine the real-world clinical practice incidence and predictive factors of venous and arterial thromboembolic events (VTE/ATE) in lung cancer patients treated with osimertinib. METHODS/PATIENTS A multicenter retrospective study including 546 lung cancer patients who initiated treatment with osimertinib...

Manuel Sánchez Cánovas, Javier López Robles, C. Fernandez-Reino et al. · Clinical and Translational O... · 0 citations

Open access Aug 2026

Body Mass Index and Body Fat Percentage Are Associated with Clinical Outcomes in Patients Receiving PD-1/PD-L1 Inhibitors: A Prospective Exploratory Study

Background/Objectives: Immunotherapy using immune checkpoint inhibitors has transformed the treatment of multiple solid tumours. However, the clinical response to programmed death receptor (PD-1) and its ligand (PD-L1) inhibitors remains heterogeneous. We have previously shown that host-related factors such as body mas...

A. Morell, A. Morell, Ainhoa Aranguren et al. · Journal of Personalized Medi... · 0 citations

Open access Sep 2026

Lung cancer after allogeneic hematopoietic stem cell transplantation.

INTRODUCTION Long-term outcomes of allogeneic hematopoietic cell transplantation (HCT) are improving, increasing the relevance of secondary malignancies, including lung cancer. The clinical utility of immune checkpoint inhibitors (ICIs) in this setting remains unclear and concerns regarding graft-versus-host disease (G...

M. Rost, C. Wehr, Miriam Mozaffari Jovein et al. · Lung Cancer · 0 citations